CYP19A1 and Cognitive impairment: The symptoms with positive responses are gastrointestinal disorders, chemotherapy-induced peripheral neuropathy, aromatase inhibitor-associated arthralgia, aromatase inhibitor-associated joint symptoms, and cognitive impairment.